NCT06627647 2026-02-12
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
AstraZeneca
Phase 3 Recruiting
AstraZeneca
Sichuan Baili Pharmaceutical Co., Ltd.
Shanghai Shengdi Pharmaceutical Co., Ltd